The 48th AGM of the Company will be held on August 25, 2026
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma's Board approved the audited consolidated financial results for FY26 ending March 31, 2026. Revenue from operations grew 14.5% year-on-year to Rs. 64,306.50 million from Rs. 56,165.04 million. Profit after tax surged to Rs. 14,583.03 million, up 93% from Rs. 7,539.13 million in FY25, driven partly by improved performance across its subsidiaries including Cenexi operations in France and Belgium. Basic EPS rose to Rs. 62.35 per share from Rs. 42.40. The Board recommended a final dividend of Rs. 20 per equity share (face value Rs. 1 each), payable within 30 days of shareholder approval at the 48th AGM on August 25, 2026. An exceptional item of Rs. 243.46 million was recognized due to additional gratuity and leave provisions under India's new labour codes that became effective from November 2025. Statutory auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion on the financial statements.
Strong earnings growth and a clean audit opinion are positive for shareholders. The 93% PAT jump and Rs. 20 dividend signal financial strength, though investors should note subsidiary-level losses of Rs. 1,566.66 million within the consolidated results.